A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
about
Erlotinib for advanced pancreatic cancerThe role of Src in solid tumorsRecent progress in pancreatic cancerRadiotherapy and "new" drugs-new side effects?Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic CancerErlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis.A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancerSmac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation.A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.Radiotherapy and erlotinib combined: review of the preclinical and clinical evidenceGemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis.Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells.Erlotinib in the treatment of advanced pancreatic cancerRadiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre raA two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.Chemoradiation therapy in the management of gastrointestinal malignancies.Biological determinants of radioresistance and their remediation in pancreatic cancer.Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?Erlotinib: applications in therapy and current status of research.
P2860
Q24186983-9FB1A961-C3B3-44F9-98AA-E40DCA713777Q24616659-6B94ED79-A73E-4CA4-903E-B054920C1DE3Q24626346-724031C2-F8E9-4D80-B4A3-6CE574EEDB90Q26861498-8FC1A44A-FEC6-4C31-8892-07EAE73F1F9AQ28552089-3E40B433-2A7D-4F37-96E8-7509735C5AB4Q33561563-27C19CA2-B7F2-4C72-B827-D3242F905E2AQ33733758-1DE05AAD-3893-4D41-8115-973D239D0032Q34326711-6EEEE955-7615-48CA-BC65-6518DD676BF3Q34342960-F5C9EFD1-C781-4BDE-9F11-25B889B800C6Q34398312-26A09F5E-3CE3-4AB1-8514-7BA17FF1EC0EQ34556212-9DC6D2BE-1385-457E-A2F4-97C39F4671F3Q34786416-F024155F-2297-45C7-AB31-A4EF4DD84613Q35050606-596199FE-A0CB-4DB6-BCC3-761016532CABQ35970960-5E88BCFE-9CB0-4E49-BE69-CC580F70C0D6Q36476666-D902807D-75AA-4E38-A7BA-48201301082EQ36916965-8C4F722A-CBDC-4422-804F-E77327380617Q37064691-1A911DC2-986C-45F4-9782-EE839005D3C6Q37179115-CD263933-85A7-4A2B-8D78-FD1E63F33630Q37307567-54A2280B-FE9E-4CB2-BFB7-9E52CE4748F9Q37403232-80708CA8-09EB-4BAC-8934-8F8E88F3640DQ37457763-6532F52B-8DE0-4AD1-98C8-5C542AF10034Q37508315-E94EEA76-3285-4C21-8C50-BB0203FE6039Q37809242-11DC9DC2-7FB9-4FF6-A910-E260C88193F6Q37854733-05A665DE-6A84-4C49-9E78-AC1C61255730Q39156722-C7D41F03-35EC-4727-895A-99808444FC7EQ39380445-8BBA10F5-2D02-454A-BEEA-36947693BD85Q54777001-192F028B-BEF4-4E84-B9AC-A64B159B7810
P2860
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase I study of erlotinib i ...... ble pancreatic adenocarcinoma.
@ast
A phase I study of erlotinib i ...... ble pancreatic adenocarcinoma.
@en
type
label
A phase I study of erlotinib i ...... ble pancreatic adenocarcinoma.
@ast
A phase I study of erlotinib i ...... ble pancreatic adenocarcinoma.
@en
prefLabel
A phase I study of erlotinib i ...... ble pancreatic adenocarcinoma.
@ast
A phase I study of erlotinib i ...... ble pancreatic adenocarcinoma.
@en
P2093
P356
P1433
P1476
A phase I study of erlotinib i ...... ble pancreatic adenocarcinoma.
@en
P2093
D P Kelsen
E M O'Reilly
G K Schwartz
J Kortmansky
P356
10.1093/ANNONC/MDM441
P577
2007-09-17T00:00:00Z